DMPA-SCDepot medroxyprogesterone acetateDMPA-IMDMPA
… (DMPA-IM) and subcutaneous injections (PA DMPA-SC), as well as DMPA-SC self-injection (SI), which enhances accessibility and continuat…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 86 of 2459dCTDSjögren’s diseasesystemic sclerosissystemic lupus erythematosusSLESScMixed connective tissue diseaseMCTD
…l study within the French MCTD cohort. IPAF, VEDOSS and current dCTD classification criteria were used to classify patients.Results …
InsulinSGLT-2iSGLT-2isGLP-1RAGLP-1RAstype 2 diabetessodium-glucose cotransporter 2 inhibitors
…d significantly after intervention (−2.0% per quarter; p=0.02). Insulin prescribing rates did not change throughout the study period. T…
SCCisiSCCinvasive squamous cell carcinoma
…erentiated.Results iSCC was most often associated with HAK-type SCCis, followed by acantholytic and FT-type SCCis, with Bowenoid type…
acute myocardial infarctionAMI-CSpVADIABPcardiogenic shockScopusVA-ECMO
…Background Mortality from cardiogenic shock complicating acute myocardial infarction (AMI-CS) is high, despite increasing mechanical circulatory sup…
Lung cancerPGS000070PGS000392LUAD
…Background Lung cancer, a leading cause of cancer deaths, is influenced by smoking, ai…
diphenhydraminedexamethasoneAmiodaronehaloperidolmetoprololketorolacrocuroniumondansetronepinephrinephenylephrine+6 more
…Drug Administration guidance.Results Amiodarone, dexamethasone, diphenhydramine, haloperidol, ketorolac, metoprolol, norepinephrine, ondansetro…
nicotineEoPschizophreniaschizoaffective disordercannabispsychosis
…ignificant.Conclusion Participants with EoP are exposed to more nicotine and tobacco-related toxicants than those without EoP, likely la…
systemic lupus erythematosusDapirolizumab pegollupus nephritisSLECDP7657BI655064SLEExplainCFZ533
…al. Dapirolizumab pegol demonstrated significant improvement in systemic lupus erythematosus disease activity: efficacy and safety results of a phase 3 tria…
CKDCVDChronic kidney diseasehaemodialysis
…nt, 74 patients (34.3%) had no evidence of CKD, 105 (49.5%) had CKD stage 3a, 24 (11.1%) stage 3b, 10 (4.6%) stage 4, and 3 (1.4%) …
semaglutidesteatohepatitisliver fibrosis
…t met all response criteria (ELF, LSM-VCTE, histology) was 16% (semaglutide) vs 5.6% (pla-cebo).The incidence of serious adverse events in …
osteoporosisPBCelafibranorosteopenia
…Imbalances were also seen in the underlying medical history for osteoporosis (elafibranor, 19.4%; placebo, 3.8%) and osteopenia (elafibranor…